Scarica l'app Stockscreener
18.84
1.07%
0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.64
Aprire:
$18.59
Volume 24 ore:
4,290
Relative Volume:
0.16
Capitalizzazione di mercato:
$143.74M
Reddito:
-
Utile/perdita netta:
$-61.23M
Rapporto P/E:
-1.3936
EPS:
-13.5194
Flusso di cassa netto:
$22.49M
1 W Prestazione:
+0.64%
1M Prestazione:
+9.28%
6M Prestazione:
+30.65%
1 anno Prestazione:
+23.14%
Intervallo 1D:
$18.40
$18.90
Intervallo di 1 settimana:
$17.93
$19.11
Portata 52W:
$7.75
$19.93
Assembly Biosciences Inc Stock (ASMB) Company Profile
Nome
Assembly Biosciences Inc
Settore
Industria
Telefono
(833) 409-4583
Indirizzo
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Confronta ASMB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
18.82 | 138.16M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.11 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.09 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.77 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
567.84 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
278.31 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-25 | Iniziato | Guggenheim | Buy |
| 2024-09-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-13 | Iniziato | H.C. Wainwright | Neutral |
| 2021-09-02 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2020-10-19 | Iniziato | Truist | Buy |
| 2019-10-16 | Iniziato | Mizuho | Buy |
| 2018-11-19 | Iniziato | Leerink Partners | Outperform |
| 2018-10-08 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-08-08 | Iniziato | Robert W. Baird | Outperform |
| 2018-04-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2017-11-08 | Iniziato | Jefferies | Buy |
| 2017-05-30 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Assembly Biosciences Inc Borsa (ASMB) Ultime notizie
How NNAGR stock performs during market volatilityShort Term Profit Focus - Newser
What makes Assembly Biosciences Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
What makes SKLZ stock price move sharplyFree Long-Term Wealth Growth Plan - Newser
When BATRK stock expected to show significant growthIs CHRS stock a good long term investment optionFree Stock Market Trend Analysis - Newser
What makes Trupanion Inc. stock price move sharplyStrong Return Daily Alerts - Newser
How CMCL stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser
Why Assembly Biosciences Inc. stock attracts strong analyst attentionFree Consultation - Newser
How Assembly Biosciences Inc. stock performs during market volatilityHigh Potential Stock Ideas - Newser
Is It Worth Buying TRINITY(trinityswap)Free Professional Portfolio Management - Newser
(ASMB) On The My Stocks Page - news.stocktradersdaily.com
Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes - Insider Monkey
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 - The Manila Times
Assembly Biosciences: A Breakthrough in Genital Herpes Treatment Could Trigger a Valuation Re-Rating - AInvest
Assembly Biosciences (ASMB) Reports Positive Phase 1b Results fo - GuruFocus
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Assembly Bio reports positive results from HBV drug trial - Investing.com
Assembly Biosciences Reports Positive Phase 1b Trial Results - TipRanks
Assembly Biosciences, Inc. (NASDAQ:ASMB) stock most popular amongst individual investors who own 48%, while public companies hold 29% - Yahoo Finance
Where are the Opportunities in (ASMB) - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 47.1% in May - Defense World
Live Biotherapeutic Products and Microbiome CDMO Market Size to Hit USD 1,496.69 Mn by 2034 - Precedence Research
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
Assembly Biosciences expands stock plans, appoints new CFO By Investing.com - Investing.com Nigeria
Assembly Biosciences expands stock plans, appoints new CFO - Investing.com
Assembly Biosciences Announces Stock Plan Amendments and Leadership Change - TipRanks
Assembly Biosciences IncJeanette M. Bjorkquist Appointed Principal Financial Officer On June 5- SEC Filing - MarketScreener
(ASMB) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares Sold by Northern Trust Corp - Defense World
When Will Assembly Biosciences, Inc. (NASDAQ:ASMB) Breakeven? - Yahoo Finance
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Up 99.2% in May - Defense World
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference - The Manila Times
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference | ASMB Stock News - GuruFocus
Assembly Bio Leadership Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics - Business Wire
Assembly Biosciences's 15-minute chart shows RSI Overbought, KDJ Death Cross. - AInvest
Assembly’s NeosAI, Powered by Microsoft Azure AI Foundry, Sets New Benchmark for Legal Productivity—Backed by Real-World Results - GlobeNewswire Inc.
Mizuho Cuts Price Target on Assembly Biosciences to $29 From $36, Keeps Outperform Rating - marketscreener.com
ABI-4334 outperforms vebicorvir in HBV suppression - BioWorld MedTech
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates - MSN
Growth Investors: Industry Analysts Just Upgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue Forecasts By 33% - simplywall.st
Assembly Biosciences First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Zacks Research Cuts Earnings Estimates for Las Vegas Sands - Defense World
Assembly Biosciences: Q1 Earnings Snapshot - New Haven Register
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences Reports Q1 2025 Earnings - TipRanks
Assembly Biosciences Inc (ASMB) Q1 2025 Earnings: EPS of -$1.17 Beats Estimate, Revenue of $9.4M Exceeds Forecast - GuruFocus
Assembly Biosciences Updates on Clinical Progress and Financials, Anticipates Key Data in 2025 - Nasdaq
Assembly Biosciences Inc Azioni (ASMB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.14%
1.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):